Pellets Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.48 Cr
as on 11-12-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 2.50 M
as on 11-12-2024
- Revenue 28.60%
(FY 2022)
- Profit 318.01%
(FY 2022)
- Ebitda 52.53%
(FY 2022)
- Net Worth 8.13%
(FY 2022)
- Total Assets 8.76%
(FY 2022)
About Pellets Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.48 Cr.
The company has closed loans amounting to ₹2.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mohan Rao, Gaddipati Basava, Pathuru Sreelatha, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239TG2004PLC042853
- Company No.
042853
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2004
- Date of AGM
12 Nov 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pellets Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pathuru Sreelatha  | Managing Director | 11-Mar-2004 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mohan Rao | Director | 11-Mar-2004 | Current |
| Gaddipati Basava | Director | 15-Jan-2005 | Current |
| Pathuru Krishna | Whole-Time Director | 18-Jul-2019 | Current |
Financial Performance of Pellets Pharma.
Pellets Pharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 28.6% increase. The company also saw a substantial improvement in profitability, with a 318.01% increase in profit. The company's net worth moved up by a moderate rise of 8.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pellets Pharma?
In 2022, Pellets Pharma had a promoter holding of 96.96% and a public holding of 3.04%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Dhanalakshmi Bank Ltd Creation Date: 29 Mar 2005 | ₹2.50 M | Satisfied |
How Many Employees Work at Pellets Pharma?
Pellets Pharma has a workforce of 177 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pellets Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pellets Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
